Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.
A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca. This story matters for Finance & Markets readers tracking finance. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. InvestorsWire.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily finance & markets signal